• Viking Therapeutics recently presented additional Phase 2 VENTURE-Oral trial data for its oral VK2735 obesity therapy at the European Congress on Obesity 2026 in Istanbul, highlighting statistically significant, dose-dependent weight loss over 13 weeks with a generally mild to moderate side-effect profile.
• The absence of a weight-loss plateau at higher VK2735 doses and the high proportion of patients reaching at least 5% and 10% weight loss underscore how this oral dual GLP-1/GIP agonist could broaden treatment options in obesity care.
• We’ll now examine how VK2735’s early, progressive oral weight-loss data may influence Viking Therapeutics’ investment narrative and future prospects.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you have to believe VK2735 can transition from promising dual GLP 1/GIP data into successful late stage outcomes that eventually support commercialization, despite today’s zero revenue and rising losses. The latest VENTURE Oral results strengthen the near term catalyst around starting Phase III oral trials, while the biggest current risk remains that any setback or delay in VANQUISH or oral Phase III plans could extend the company’s cash burn without a clear path to product income.

The ECO 2026 poster on VENTURE Oral is especially relevant because it adds detail on dose dependent, statistically significant weight loss and tolerability in a real world like obesity population, which sits alongside the ongoing, longer duration VANQUISH 1 and VANQUISH 2 injectable trials. Together, these updates frame how oral and injectable VK2735 could become parallel value drivers, but they also raise the stakes if future data, regulatory feedback or competitive shifts are less favorable than investors expect.

Yet investors should also weigh how quickly rising R&D spend and Viking’s dependence on VK2735 could backfire if Phase III timelines slip or regulators ask for more data than...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This implies an earnings increase of about $372.5 million from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 192% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were assuming about US$497.5 million of revenue and US$62.2 million of earnings by 2029, paint a far more aggressive upside than consensus. Compared with the more cautious view that focuses on execution and funding risk around VK2735, these bullish forecasts highlight how opinions can diverge sharply, especially as fresh oral Phase II data emerge and could reshape how you think about VK2735 as a second high value product path.

Explore 16 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.